Search

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To perform clinical comprehensive evaluation of total glucosides of paeony capsules in the treatment of recurrent oral ulcer based on evidence-based evidence, so as to provide reference for clinical rational drug use. METHODS: Wangfang Data, CNKI, CBM, PubMed, Embase, the Cochrane Library, the International Health Technology Assessment Network, the International Health Technology Assessment Association and other websites were systematically retrieved to collect clinical research, pharmacoeconomic research, safety evaluation and other data of total glucosides of paeony capsules in the treatment of recurrent oral ulcer (the search deadline was from database establishment to Nov. 30th, 2022). The quality of literature and its methodology were evaluated and analyzed. RESULTS: A total of 15 articles were included, including 12 clinical studies and 3 safety evaluations, pharmacoeconomics studies were not included. The total glucoside of paeony capsules has certain advantages in the treatment of recurrent oral ulcer in improving the total effective rate, shortening the ulcer healing time, reducing pain score, improving the level of inflammatory factors, improving immune function, and promoting the long-term curative effect. The safety study results showed that the total glucoside of paeony capsules had higher safety and lower incidence of adverse drug reactions in clinical use, and combined treatment with other western drugs could effectively reduce the occurrence of adverse drug reactions and enhance patient compliance. Results of drug accessibility evaluation showed that total glucosides of paeony capsules had good availability, affordability, convenience and acceptability in the treatment of recurrent oral ulcer. CONCLUSIONS: Total glucosides of paeony capsules can significantly improve the total effective rate, improve the quality of life of patients, relieve pain, and has higher safety in the treatment of recurrent oral ulcer, yet there is a lack of literature on pharmacoeconomics. In the future, more standardized clinical observation and related pharmacoeconomics research should be further carried out to supplement evidence of higher quality. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To evaluate the efficacy, economical efficiency and safety of compound Kushen injection in the treatment of non-small cell lung cancer (NSCLC), so as to provide evidence for clinical rational drug use. METHODS: CBM, CNKI, Wanfang Data, INAHTA and HTAI databases or organization websites, PubMed, the Cochrane Library and Embase were retrieved to collect health technology assessment (HTA) reports, Meta-analysis/ systematic review, and pharmacoeconomic studies of compound Kushen injection in the treatment of NSCLC (search deadline was until Sept. 30th, 2022). The quality of literature and its methodology were evaluated and analyzed. RESULTS: A total of 13 articles were included. Among them 11 studies were conducted on Meta-analysis/ systematic review, 2 studies were conducted on pharmacoeconomics, HTA were not obtained. Results showed that compound Kusen injection in the treatment of NSCLC had certain advantages in improving the total effective rate, disease control rate and one-year survival rate, improving the quality of life of patients and relieving pain. Results of safety study showed that compound Kushenshen injection combined with radiotherapy and chemotherapy in the treatment of NSCLC could effectively reduce adverse drug reactions with higher safety. In pharmacoeconomic evaluation, compound Kushen injection was compared with blank control and Aidi injection, results showed that compound Kushen injection combined with chemotherapy could improve the quality of life and prolong the survival time of patients, and had certain cost-utility advantages. However, it was economically inferior compared with Addy injection. CONCLUSIONS: Compound Kushen injection in the treatment of NSCLC can help to improve clinical efficacy and evaluation indicators, reduce the toxic and side effects of radiotherapy and chemotherapy. In the future, more standardized clinical observation and related pharmacoeconomic research need to be further carried out to supplement higher-quality evidence-based evidence. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To evaluate the efficacy, safety and economical efficiency of Shuxuening injection in the treatment of ischemic stroke by the evidence-based evidence,so as to provide reference for clinical rational drug use. METHODS: Retrieved from Wanfang Data, CBM, CNKI, PubMed, the Cochrane Library, Embase, International Network of Agencies for Health Technology Assessment and Health Technology Assessment International and other websites, health technology assessment (HTA) reports, Meta-analysis/systematic reviews and pharmacoeconomic studies related to Shuxuening injection in the treatment of ischemic stroke were sorted and analyzed. The quality evaluation was performed on the literature and their methodology. RESULTS: A total of 22 literature were included, among which, 10 studies were conducted on Meta-analysis/systematic reviews,12 studies were conducted on pharmacoeconomics, HTA reports were not obtained. The results of efficacy studies showed that Shuxuening injection in adjuvant treatment of ischemic stroke have certain advantages in increasing the total effective rate, improving neurological deficit score and brain CT results, laboratory indicators (whole blood viscosity, plasma viscosity, fibrinogen, erythrocyte aggregation index, hematocrit), improving National Institutes of Health Stroke Scale score and Modified Edinburgh-Scandinavian Stroke Scale score. Safety studies showed that the adverse drug reactions of Shuxuening injection were mainly allergic-like reactions, and most of them could be resolved spontaneously after drug withdrawal. Results of pharmacoeconomic evaluation showed that Shuxuening injection did not possess economic advantages compared with Ginkgolide injection, Yinxing damo injection, Vinpocetine injection, etc. ; the costeffectiveness ratio of Shuxuening injection was better compared with Xueshuantong for injection, Acanthopanax senticosus injection, Ixeris sonchifolia injection, Edaravone injection, etc. ; the results of pharmacoeconomic evaluation were inconsistent compared with Xuesaitong injection. CONCLUSIONS: Shuxuening injection in adjuvant treatment of ischemic stroke can improve clinical efficacy and improve evaluation indicators. In the future, more standardized clinical observation and related pharmacoeconomic research need to be further carried out to supplement higher-quality evidence-based evidence. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To evaluate the efficacy, safety and economical efficiency of Shenmai injection in the treatment of malignant tumor by the evidence-based proof, so as to provide evidence for clinical rational medication. METHODS: Health technology assessment (HTA) reports, systematic reviews/ Meta-analysis and pharmacoeconomic researches of Shenmai injection in the treatment of malignant tumor were retrieved from Wanfang Data, CBM, CNKI, PubMed, the Cochrane Library, Embase, International Network of Agencies for Health Technology Assessment (INAHTA) and Health Technology Assessment international (HTAi) organization websites, the retrieved data were analyzed and summarized, and the quality evaluation was performed on the literature and its methodology. RESULTS: A total of 11 studies were involved, including 10 systematic reviews/ Meta-analysis, 1 pharmacoeconomic researches, no HTA were obtained. The results show that Shenmai injection for adjuvant therapy in malignant tumor had certain advantages in increasing total effective rate and disease control rate, promoting Traditional Chinese Medicine(TCM) symptom score and Karnofsky score, improving quality of life and immune function, decreasing the incidence of myelosuppression, reducing peripheral neurotoxicity, improving leukopenia, decreasing ECG abnormalities, myocardial enzyme abnormalities and cardiac functional damage; meanwhile, the adverse drug reactions of Shenmai injection was mainly anaphylactic reactions. Pharmacoeconomic evaluation results showed that Shenmai injection combined with chemotherapy can help improve the clinical symptoms of TCM in tumor patients, but its C / E and ΔC / ΔE were not optimal compared with other TCM injections. CONCLUSIONS: Shenmai injection can improve the immune function of patients and reduce the adverse drug reactions of radiotherapy and chemotherapy in the adjuvant treatment of malignant tumors. Furthermore, more standardised clinical observations and related pharmacoeconomic studies are needed to supplement the higher quality of evidence-based evidence for drug application. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To rapidly evaluate the efficacy, safety and economical efficiency of Shengmai injection in the treatment of cardiac failure based on rapid health technology assessment(HTA), so as to provide evidence-based evidence for clinical rational drug use. METHODS: Wanfang Data, CNKI, CBM, the Cochrane Library, Embase, PubMed and HTA organization websites (HTAi and INAHTA) were searched systematically, HTA reports, systematic reviews/ Meta-analysis and pharmacoeconomic studies of Shengmai injection in the treatment of heart failure were included. The included data were summarized and analyzed, and the quality of literature and methodology was evaluated. RESULTS: A total of 12 literature were included, including 9 systematic reviews/ Meta-analysis and 3 pharmacoeconomic studies, yet no HTA report was retrieved. The results show that Shengmai injection combination with western medicine in the treatment of cardiac failure can improve the total effective rate, increase the left ventricular ejection fraction ( LVEF), 6 min walking test distance, cardiac output, stroke volume, improve New York Heart Association cardiac function classification, Minnesota heart failure quality of life scale score and cardiac index, reduce the N-terminal pro-B-type natriuretic peptide level, left ventricular end-diastolic diameter. In terms of improving the short-axis shortening rate of the left ventricle and reducing the level of brain natriuretic peptide, the conclusions of various studies were inconsistent. Meanwhile, the incidence of adverse drug reactions of Shengmai injection was similar to that of the control regimen. CONCLUSIONS: Shengmai injection can effectively improve the clinical symptoms of heart failure. In the future, more in-depth pharmacoeconomic studies and more standardized clinical observation and safety evaluation of the drug can be carried out to supplement relevant evidence-based evidence for medication. [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To systematically evaluate the efficacy and safety of Silibinin capsules and Hugan tablets in improving fatty liver-related biochemical indicators. METHODS: Wanfang Data, CBM, CNKI, the Cochrane Library, Embase and PubMed database were retrieved to collect the randomized controlled trials of Silybin capsule and Hugan tablets in the treatment of fatty liver( the study group was treated with Silibinin capsules and the control group received Hugan tablets). The retrieval time was from the establishment of the database to Oct. 2021. After extracting data, selecting literature and evaluating the risk of bias for the included literature, Rev Man 5. 4 software was used for Meta analysis. METHODS: Totally 9 literature were enrolled, including 700 patients ( 3 84 patients in the study group and 316 patients in the control group). Meta-analysis results showed that the total effective rate ( OR = 4. 39, 95%CI= 2. 95-6. 55, P

OBJECTIVE: To rapidly evaluate the efficacy,safety and economical efficiency of Xingnaojing injection in the treatment of stroke,so as to provide evidence-based reference for clinical rational medication.METHODS: WanFang database,CNKI,CBM,Embase,PubMed and the Cochrane Library were searched,health technology assessment reports,systematic reviews/Meta-analyses and pharmacoeconomic studies related to Xingnaojing injection in the treatment of stroke were enrolled. The included data were analyzed and summarized,and quality evaluation was performed on the literature and its methodology. RESULTS: A total of 28 studies were involved,of which 21 were systematic evaluations/Meta-analyses,7 were pharmacoeconomic studies, no health technology assessment reports were retrieved. The result showed that Xingnaojing injection combined with conventional regimens in the treatment of stroke can improved patients’ clinical symptoms by inhibiting the cascade reaction after cerebral hemorrhage and reduced the mortality in patients with cerebral hemorrhage; it also had significant advantages in improving the living capability index of stroke patients,promoting the scores of National Institutes of Health Stroke Scale and European Stroke Scale,improving the neurological deficits and coma level in patients with stroke combined with impaired consciousness,reducing volume of cephalophyma and improving various hemorheological indicators;however,it had no significant effect on the cure rate of patients; meanwhile,there were no serious adverse drug reactions occurred during treatment,which had good safety. CONCLUSIONS: Xingnaojing injection has good efficacy and safety in the treatment of stroke. In the future,more in-depth pharmacoeconomic studies and more standardized clinical observation studies can be conducted to supplement the relevant economic evaluation evidence. [ABSTRACT FROM AUTHOR]

OBJECTIVE: Based on evidence-based pharmacy, to evaluate the effectiveness and safety of Qianglidingxuan tablets (capsules) combined with Betahistine in the treatment of vertigo. METHODS: Computer searched Embase, PubMed, the Cochrane Library, Wanfang database, CNKI and China Biomedical Literature Database, and included Qianglidingxuan tablets (capsules) combined with betahistine in the treatment of vertigo in randomized controlled trials [the study group plan is Qianglidingxuan tablets (capsules) combined with betahistine treatment, the control group was treated with betahistine alone], the retrieval time was from the establishment of the database to June 2021. After 2 researchers extracted data, selected literature, and evaluated the risk of bias in the included literature, Rev Man 5.4 software was used to conduct a meta-analysis (Meta analysis). RESULTS: A total of 11 randomized controlled trials were included, including 956 patients (478 patients in the study group and 478 patients in the control group). Meta-analysis results show that, in terms of effectiveness, the total effective rate (OR=5.19, 95%CI=3.33-8.10, P <0.000 01) and significant rate (OR=2.09, 95%CI=1.57-2.78, P<0.000 01), recovery rate (OR=3.75, 95%CI=1.86～7.55, P=0.000 2), vertigo symptom score (MD=-4.40, 95%CI=-4.82～-3.98, P<0.000 01 ), vertigo disorder scale score (MD=-10.57, 95%CI=-11.92～-9.22, P<0.000 01), plasma viscosity (MD=-0.25, 95%CI=-0.32～-0.17, P<0.000 01), left vertebral artery blood flow velocity (MD=4.56, 95%CI=3.38～5.74, P<0.000 01), right vertebral artery blood flow velocity (MD=4.37, 95%CI=3.85～4.90, P<0.000 01), basilar artery blood flow velocity (MD=3.49, 95%CI=2.68～4.31, P<0.000 01), endothelin 1 level (MD=-29.72, 95%CI=-31.29～-28.15, P<0.000 01), the level of calcitonin gene-related peptide (MD=6.21, 95%CI=5.43～6.99, P<0. 000 01) and the ratio of endothelin 1/calcitonin gene-related peptide (OR=-2.01, 95%CI=-2.38～-1.63, P<0.000 01) were significantly better than the control group, and the differences were statistically significant; In terms of safety, there was no significant difference in the incidence of adverse reactions between the two groups of patients (OR=0.59, 95%CI=0.14～2.53, P=0.47>0.05). CONCLUSION: Existing evidence shows that Qianglidingxuan tablets (capsules) combined with betahistine are safe and effective in the treatment of vertigo, which has significant advantages over betahistine alone. Due to the limitation of the number and quality of included studies, the above conclusions need to be verified by more high-quality randomized controlled trials in the future. [ABSTRACT FROM AUTHOR]

OBJECTIVE: Based on the rapid health technology assessment(HTA),to evaluate the efficacy,safety and economical efficiency of Shenfu injection in the treatment of cardiac failure, so as to provide evidence-based evidence for clinical rational drug application. METHODS: HTA reports, systematic reviews/ Meta-analyses and pharmacoeconomic studies on Shenfu injection in the treatment of cardiac failure were involved by overall retrieving CNKI,Wanfang database,CBM,EMBase,PubMed and the Cochrane Library,qualitative description was adopted to conduct analysis and summary on the involved studies,and quality evaluation on the literature and its methodology were performed. RESULTS: Totally 14 studies were involved,13 of which were systematic reviews/ Meta-analyses,1 was pharmacoeconomic study,no HTA report was retrieved. The analysis result indicated that the combination of Shenfu injection and western conventional therapy in the treatment of cardiac failure had obvious advantages in promoting clinical effective rate, improving TCM syndrome score, reducing brain natriuretic peptide level, improving left ventricular ejection fraction, increasing cardiac output, improving heart pump function, reduce N-terminal B-type pronatriuretic peptide level, promoting 6-min walking distance, improving left ventricular shortening fraction and reducing readmission rate of patients with cardiac failure; however, the research conclusions on reducing the left ventricular end diastolic diameter and mortality were inconsistent; meanwhile, no obvious adverse drug reactions [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)